Imago BioSciences, Inc. (IMGO): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMGO Stock Price Chart Interactive Chart >
IMGO Price/Volume Stats
| Current price | $16.34 | 52-week high | $35.68 |
| Prev. close | $15.33 | 52-week low | $12.85 |
| Day low | $14.95 | Volume | 104,400 |
| Day high | $16.37 | Avg. volume | 230,775 |
| 50-day MA | $17.49 | Dividend yield | N/A |
| 200-day MA | $21.08 | Market Cap | 551.25M |
Imago BioSciences, Inc. (IMGO) Company Bio
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Latest IMGO News From Around the Web
Below are the latest news stories about Imago BioSciences Inc that investors may wish to consider to help them evaluate IMGO as an investment opportunity.
Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 10:30 a.m. PT / 1:30 p.m. ET. Interested partie |
PepGen Appoints Laurie Keating as Chair of Board of DirectorsKeating brings strong experience as a life science executive and Board memberBOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of |
Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
38 Stocks Moving In Tuesday''s Mid-Day SessionGainers Reliance Global Group, Inc. (NASDAQ: RELI ) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI ) climbed 71.4% to $13.06 after gaining over 7% on Monday. Biofrontera recently announced the first subject has been enrolled in the Phase 2b study to evaluate the safety and efficacy of Ameluz in combination with the red-light lamp BF-RhodoLED for acne. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS ) jumped 36% to $3.4550 after the company reported pan-coronavirus monoclonal antibody cocktail that retains effectiveness against the omicron variant, other covid-19 variants, SARS, MERS, and the common cold human coronaviruses. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) shares climbed 33.8% to $4.55. Evofem Biosciences, Inc. (NASDAQ: EVFM ) rose 24.1% to... |
Imago BioSciences (NASDAQ:IMGO) Shares Up 15.8%Imago BioSciences Inc (NASDAQ:IMGO) shares shot up 15.8% during mid-day trading on Tuesday . The company traded as high as $25.71 and last traded at $25.70. 3,025 shares were traded during mid-day trading, a decline of 99% from the average session volume of 241,524 shares. The stock had previously closed at $22.20. A number of [] |
IMGO Price Returns
| 1-mo | -0.06% |
| 3-mo | -30.62% |
| 6-mo | -26.96% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -31.08% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...